The CL R of SNAC based on 0–36 h after the tenth dosing decreased with severe renal impairment. Table 2 Pharmacokinetic endpoints for semaglutide after the tenth dosing Parameters Renal function group (full analysis set) Normal (n = 24) Mild ( n = 12) Moderate ( n = 12) Severe ( n = 12) ESRD ( n = 11) AUC24,Day10 (nmol/C1h/L) 283.7 (53.3) 378.2 (78.9) 298.5 (107.3) 163.5 (65.6) 287.7 (128.7) Cmax,Day10 (nmol/L) 14.9 (53.2) 20.2 (75.9) 16.6 (102.0) 8.6 (62.9) 15.7 (128.3) tmax,Day10 (h) 1.0 (0.5, 4.0) 1.0 (0.5, 2.5) 1.0 (0.5, 4.0) 1.5 (0.5, 4.0) 1.0 (0.5, 2.0) t/C145(h) 151.7 (9.1) 159.3 (12.0) 162.8 (11.2) 164.9 (8.9) 152.8 (49.0) Data are geometric means (coefﬁcient of variation) except for tmax,Day10 where median (minimum, maximum) values are presented AUC24,Day10 area under the plasma concentration–time curve from time zero to 24 h after the tenth dose, Cmax,Day10 maximum plasma con- centration 0–24 h after the tenth dose, ESRD end-stage renal disease, tmax,Day10 time to reach Cmax,Day10, t/C145terminal half-life 0 100 200 300 400 500 600 700 1.37 [0.91; 2.06] AUC24,Day10  Normal Mild Moderate Severe ESRD Normal Mild Moderate Severe ESRD 0  5  10  15  20  25  30  35  40  Cmax (nmol/L) AUC0–24h (nmol·h/L) Cmax,Day10  1.13 [0.69; 1.84]  1.02 [0.59; 1.79]  1.39 [0.93; 2.06]  1.20 [0.75; 1.93]  0.61 [0.42; 0.87] 0.61 [0.42; 0.88]  1.06 [0.61; 1.84]  Fig. 3 AUC24,Day10 and Cmax,Day10 for semaglutide after the tenth dose by renal function. 